it sounds like this new medication is a game-changer.
at the beginning of 2013, health canada approved eculizumab (solaris) for the treatment of ahus. we were very optimistic, after all, this drug by all accounts was well tolerated by patients and had very few side effects. of course, there are some, but it’s nothing like having a massive disease. it was safe to use and effective at keeping the disease from getting out of control. it felt almost like a miracle to have something like it available.
but then we found out that it was one of the most, if not the most, expensive drug in the world.
all provinces in canada, except for quebec, refused to fund it for patients. so, here we were, there was a treatment to control the disease, but it wasn’t available because of the price. it didn’t help that there was a report by health canada saying there wasn’t enough proof the drug was effective, but that was really only based on the fact that there are so few patients with ahus.
we decided to try to fix that problem by lobbying the government to show that even though the data wasn’t exactly what they wanted, it was still good data. i mean, if you got 1,000 patients and 950 of them respond really well to a treatment versus 100 patients and 95 of them respond well, yes, the 1,000 and 950 is better data. but it can’t just negate the lesser data — it still was in our mind clear enough that this was a really good drug.
were you successful getting the drug approved?
the drug is now available [for ahus patients who are receiving a kidney transplant]. now there’s a chance to have a kidney transplant in the future. i’m looking forward to that day when the call comes in and i can have a new kidney that will be protected by this drug.
we’re still not exactly where we want to be. there’s always the fear from the province that if it gives the decision making powers to doctors, then a doctor might over-prescribe, or be influenced by a patient’s pleading, and then an expensive drug will be wasted on someone who doesn’t need it. this means that there’s very strict criteria in order to receive this drug.